Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2016

Date: August 31, 2016
Pages: 131
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: MBB2FADFA53EN
Leaflet:

Download PDF Leaflet

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2016’, provides an overview of the Metastatic Hepatocellular Carcinoma (HCC) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Hepatocellular Carcinoma (HCC) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Metastatic Hepatocellular Carcinoma (HCC)
  • The report reviews pipeline therapeutics for Metastatic Hepatocellular Carcinoma (HCC) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Metastatic Hepatocellular Carcinoma (HCC) therapeutics and enlists all their major and minor projects
  • The report assesses Metastatic Hepatocellular Carcinoma (HCC) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Metastatic Hepatocellular Carcinoma (HCC)
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Metastatic Hepatocellular Carcinoma (HCC) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Metastatic Hepatocellular Carcinoma (HCC) Overview
Therapeutics Development
Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) - Overview
Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis
Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics under Development by Companies
Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics under Investigation by Universities/Institutes
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Metastatic Hepatocellular Carcinoma (HCC) - Products under Development by Companies
Metastatic Hepatocellular Carcinoma (HCC) - Products under Investigation by Universities/Institutes
Metastatic Hepatocellular Carcinoma (HCC) - Companies Involved in Therapeutics Development
Acceleron Pharma, Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Celgene Corporation
Eisai Co., Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
HanAll Biopharma Co., Ltd.
Johnson & Johnson
Millennium Pharmaceuticals Inc
Mirna Therapeutics, Inc.
Molecular Partners AG
MolMed S.p.A.
Novartis AG
OncoMed Pharmaceuticals, Inc.
Pfizer Inc.
PharmAbcine, Inc.
Verlyx Pharma Inc.
Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AV-203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-9150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-122 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy for Metastatic Hepatocellular Carcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
codrituzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crizotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dalantercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emibetuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erdafitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
golvatinib tartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HL-143 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ipafricept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3039478 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3127804 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-0250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MRX-34 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGR-hTNF - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OSU-2S - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palbociclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pasireotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentamidine isethionate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-04518600 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PTX-9908 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sapanisertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sonidegib phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
temsirolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TTAC-0001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
utomilumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Metastatic Hepatocellular Carcinoma (HCC) - Dormant Projects
Metastatic Hepatocellular Carcinoma (HCC) - Discontinued Products
Metastatic Hepatocellular Carcinoma (HCC) - Product Development Milestones
Featured News & Press Releases
Jul 30, 2013: Mirna Therapeutics Announces Important Expansion of microRNA Patent Portfolio
May 13, 2013: Marina Biotech's Licensee Mirna Therapeutics Initiates Phase I Clinical Trial Of Anticancer Drug MRX34
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC), H2 2016
Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Acceleron Pharma, Inc., H2 2016
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by AstraZeneca Plc, H2 2016
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Celgene Corporation, H2 2016
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Eisai Co., Ltd., H2 2016
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Eli Lilly and Company, H2 2016
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by HanAll Biopharma Co., Ltd., H2 2016
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Johnson & Johnson, H2 2016
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Mirna Therapeutics, Inc., H2 2016
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Molecular Partners AG, H2 2016
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by MolMed S.p.A., H2 2016
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Novartis AG, H2 2016
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Pfizer Inc., H2 2016
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by PharmAbcine, Inc., H2 2016
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Verlyx Pharma Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Metastatic Hepatocellular Carcinoma (HCC) - Dormant Projects, H2 2016
Metastatic Hepatocellular Carcinoma (HCC) - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC), H2 2016
Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Acceleron Pharma, Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Celgene Corporation
Eisai Co., Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
HanAll Biopharma Co., Ltd.
Johnson & Johnson
Millennium Pharmaceuticals Inc
Mirna Therapeutics, Inc.
Molecular Partners AG
MolMed S.p.A.
Novartis AG
OncoMed Pharmaceuticals, Inc.
Pfizer Inc.
PharmAbcine, Inc.
Verlyx Pharma Inc.
Skip to top


Ask Your Question

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: